… for QR-110 from the FDA. The planned Phase 1/2 open-label trial (PQ-110-001) will include approximately 6 … 6 adults (≥ 18 years) that have LCA 10 due to one or two copies of the p.Cys998X mutation. During the trial, patients … with expertise in genetic retinal disease in the US and Europe. The primary objective will be to assess safety and …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in … Equity settled Option Employee premium …
… ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results LEIDEN, The Netherlands & … financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …
QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course
QR-110 was well-tolerated with no serious adverse events
… ProQR Announces First Quarter 2020 Operating and Financial Results Reported positive interim … financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …
… Meeting of the Association for Research in Vision and Ophthalmology (ARVO) the company presented pre-clinical data … LCA 10 compound heterozygous patient cells and homozygous optic cups in a dose dependent manner. Based on this data, … QR-010 is designed to be self-administered via an optimized eFlow® Nebulizer (PARI Pharma GmbH). eFlow® is a …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …